UPenn Perelman School of Medicine: ASCO - New 'Armored' CAR Produces Significant Responses in Patients Whose Cancers Don't Respond to Current CAR T Cell Therapies
June 03, 2024
June 03, 2024
CHICAGO, Illinois, June 3 (TNSres) -- The University of Pennsylvania's Perelman School of Medicine issued the following news release on June 1, 2024:
* * *
Phase I clinical trial also uses shorter, three-day manufacturing process for CAR T
* * *
While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission. . . .
* * *
Phase I clinical trial also uses shorter, three-day manufacturing process for CAR T
* * *
While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission. . . .